Placebo to fluticasone/salmeterol

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 3

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01315249

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2011-03-31End: 2012-03-31Updated: 2013-08-09

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

CompletedNCT01709903

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2012-11-30End: 2014-02-28Updated: 2015-03-17

Related Papers

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.

2016-10-017 citations

Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study

COPD Journal of Chronic Obstructive Pulmonary Disease2016-08-114 citations

QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies

Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2014-01-018 citations

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

2012-12-06224 citations